抑制性和激发性突触神经适应在耐受泽的脑中
Joshua M Lorenz-Guertin1, Nadya Povysheva2, Caitlyn A Chapman1
1Department of Pharmacology and Chemical Biology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Neurobiology of disease
|August 3, 2023
概括
二胺耐受性通过改变大脑信号来降低药物的有效性. 鼠标显示GABAergic抑制降低,Glutamatergic刺激增加,破坏治疗效果所需的平衡.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 分子生物学分子生物学
背景情况:
- 类药物 (BZ) 通过增强GABA型A受体 (GABAAR) 活性,被广泛用于治疗焦虑,失眠和发作.
- BZs的临床使用受到耐受性和戒断的限制,包括增加发作风险和睡眠障碍.
- 了解BZ耐受性背后的神经生物学机制对于改善治疗策略至关重要.
研究的目的:
- 为了研究与二二胺耐受性相关的抑制GABAergic和激发性谷氨基基基路的神经质变化.
- 阐明GABAAR亚单元组成和信号通路中的分子适应,有助于降低BZ有效性.
主要方法:
- 使用了一种小鼠模型,用于测试亚泽 (DZP) 诱导的耐受性.
- 评估了突触电流,GABAAR亚单元水平,以及强力抑制.
- 量化激发性谷氨基基酶传递,NMDAR亚单元表达,以及皮质信号通路的蛋白质组分析.
主要成果:
- 重复的西巴姆治疗导致镇静效应减弱,并减少了突触GABAAR电流的强化.
- 观察到GABAAR亚型的转变,突触α4含有的受体增加和强力抑制降低.
- 发现激发性谷氨基基基因传输增加,NMDAR子单元上调,皮质信号通路改变 (CAMKII,MAPK,PKC).
结论:
- 降低抑制性GABAergic调和增强的谷氨酸激素神经传递有助于破坏BZ耐受性中的刺激/抑制平衡.
- 这些神经适应是二的治疗功率下降的基础,并可能导致戒断症状.
相关概念视频
Long-term Depression
2.6K
Long-term depression, or LTD, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTD is the process of synaptic weakening that occurs over time between pre and postsynaptic neuronal connections. The synaptic weakening of LTD works in opposition to synaptic strengthening by long-term potentiation (LTP) and together are the main mechanisms that underlie learning and memory.
Calcium Ion Concentration Mechanism
If over...
Calcium Ion Concentration Mechanism
If over...
2.6K
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.3K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.3K
CNS Depressants: Barbiturates and Benzodiazepines
322
CNS depressants include drugs from the category of barbiturates and benzodiazepines. They are valuable medications for managing anxiety disorders and insomnia. Barbiturates, once used to induce and maintain sleep, have been replaced mainly by benzodiazepines due to barbiturate's toxicity, tolerance, and overdose risks. They interact with GABAA receptors, leading to sedation at low doses and potentially coma and death at higher doses. Phenobarbital, a long-acting barbiturate, possesses...
322
Antiepileptic Drugs: GABAergic Pathway Potentiators
461
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
461
Excitatory and Inhibitory Effects of Neurotransmitters
10.1K
When an action potential reaches the presynaptic axon terminal, it releases neurotransmitters from the neuron into the synaptic cleft at a chemical synapse. The released neurotransmitter can be excitatory or inhibitory. The critical criteria commonly used to determine whether a molecule is a neurotransmitter at a chemical synapse are the molecule's presence in the presynaptic neuron. Second, its release is in response to strong presynaptic depolarization. And lastly, the presence of...
10.1K
Sedatives and Hypnotics Drugs: Benzodiazepines
294
Benzodiazepines have both sedative and hypnotic properties. They include compounds such as diazepam (Valium) and alprazolam (Xanax). Structurally, their cores are similar, consisting of the fusion of a benzene ring and a diazepine ring, but they share a common mechanism of action in the central nervous system (CNS).
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
Benzodiazepines work by enhancing the effects of the inhibitory neurotransmitter GABA. They bind to the GABAA receptor, increasing its affinity for GABA, which opens chloride...
294


